PlasmaTech Biopharmaceuticals, Inc. (NASDAQ:PTBI) has announced that the appointment of Todd Wider as the MD of the Board of Directors. The focus of this biopharmaceutical company is gene therapy and advancing cell therapy for rare diseases. The company announced the election of Wider, who has a strong medical background and a good amount of experience in mid-cap and small biotechnology companies.
The Executive Chairman of the Company, Steven H. Rouhandeh, has said that the members of the board are very much pleased with this new development and at having Wider as the company’s MD. While appreciating the attributes of Wider, Rouhandeh said that the newly appointed MD has a unique blend of both experience and skills and is sure to add great value to the company. The Executive Chairman was hopeful that Wider would contribute in the building of the product pipeline related to gene and cell therapies focusing on the rare diseases.
Todd Wider passed graduation with high honors from the Princeton University and completed his MD from the Columbia College of Physicians and Surgeons. Apart from having vast experience in surgery, Wider has worked extensively in the biotechnology investment community. He has been working as a consultant to leading investors in the healthcare institution for many years.
The various fields in which he worked includes private and public financings, licensing transactions in the medical, biotechnology industries, and corporate development.
PlasmaTech- Focused on Gene and Cell Therapy
PlasmaTech is basically more focused on coming up with solutions for treating rare diseases through gene and cell therapy. At present, the company is pursuing a gene therapy in collaboration with the researchers, clinicians and patient advocate groups for Sanfilippo Syndrome (MPS IIA and IIB). The Sanfilippo types A and B clinical trials will be starting in the mid of 2015. Apart from these therapies, PlasmaTech is also trying to work on two additional proprietary platforms. These include the Salt Diafiltration (SDF) Process and the Polymer Hydrogel Technology (PHT).
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: